AstraZeneca and CSPC Pharmaceutical have signed a research deal worth up to USD 5.3 billion to co-develop oral therapies for chronic and immunological diseases. CSPC will lead discovery in China using ...

Cambridge: AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group ...

A formal tender, worth £23 million a year, is due to be issued in August. However, the preliminary notice is open to ...